CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 193 enrolled
Drug / intervention
Parenchymal Intracranial pressure monitor +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05593380
NCT05593380N/ACompleted

The Impact of Invasive Intracranial Pressure Monitoring Guided Management on the Functional Outcomes of Patients With Supratentorial Large Volume Cerebral Hemorrhage: An Open Label, Randomized, Controlled, Multi-center Trial (BIATICH)

Xiangya Hospital of Central South University·interventional·Posted Oct 25, 2022·Updated Sep 8, 2025

In Brief

A clinical study evaluating Parenchymal Intracranial pressure monitor and Treatment based on clinical and imaging observations for Cerebral Hemorrhage, Hypertensive and 6 related conditions. Completed, enrolled 193 participants across 17 sites.

Detailed Summary

Spontaneous cerebral hemorrhage (SICH) is a hemorrhage caused by the rupture of a blood vessel within the brain parenchyma that is non-traumatic. Its rapid onset and dangerous condition seriously threaten human health; it accounts for about 15% of strokes and 50% of stroke-related mortality. Hunan Province is recognized as one of the high incidence areas of cerebral hemorrhage in the world; according to statistics, the direct economic loss caused by cerebral hemorrhage in Hunan Province is more than 1 billion yuan per year, which should be paid great attention. A 30-day follow-up study of large-volume cerebral hemorrhage (defined as supratentorial hemorrhage greater than 30 ml, infratentorial greater than 5 ml, and thalamus and cerebellum greater than 15 ml) found that the morbidity and mortality rate of ICH with hemorrhage of 30-60 ml was as high as 44-74%, while the morbidity and mortality rate of ICH with hemorrhage of \<30 ml was 19% and that of \>60 ml was 91%. According to studies, the occurrence of hematoma occupancy and malignant cerebral edema in large-volume cerebral hemorrhage can lead to secondary malignant intracranial pressure elevation and subsequent secondary brain injury, which are the main factors of high morbidity and mortality and poor prognosis in patients with large-volume cerebral hemorrhage. Clinical monitoring and management is the key to treatment, and despite aggressive surgical treatment and anti-brain edema therapy, a large number of patients progress to malignant brain edema disease, leading to poor outcomes. This study aims to conduct a multicenter clinical trial in China investigating the role of invasive intracranial pressure (ICP) monitoring in managing patients with large-volume supratentorial intracerebral hemorrhage. The trial will evaluate whether ICP-guided treatment protocols for cerebral edema improve patient outcomes and generate evidence to support the clinical application of invasive ICP monitoring in this patient population.

Study Details

Timeline

N/ACompletedFinished
2023202420252026
First PostedOct 25, 2022
Enrollment StartNov 15, 2022
Primary CompletionJun 26, 2025
Study CompletionJul 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 3.7 years ago

Interventions

Parenchymal Intracranial pressure monitordevice

Treatment based on readings from Parenchymal intracranial pressure monitor.

Treatment based on clinical and imaging observationsother

Treatment based on clinical and imaging observations.